solicitation to purchase or subscribe for securities in the United States, Australia, Canada or Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. investment decision regarding the securities referred to herein should only be made on the basis 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. Contact Us - Nextpoint Questions about Nextpoint? If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. our employees, International Further, it does Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. Hub Langenfeld, Accelerate As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. We'd love to talk to you. Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Insect Decline, Raising By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. These materials may not be transmitted over the Website without the copyright owners permission or without a legitimate fair use justification for the transmittal. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. expression Prospectus Directive includes any relevant implementing measure in each Relevant Member Sanofi Ventures is the corporate venture capital arm of Sanofi. & Impact, Benefits Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. Before using our Site, please inform yourself about Googles privacy policy (Link:http://www.google.com/privacy.html). Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser. Prospectus Directive. Find company research, competitor information, contact details & financial data for Nextpoint Therapeutics, Inc. of Cambridge, MA. Leaps by Bayer and Sanofi Ventures co-led the round and were joined . Therapies against immune checkpoints have revolutionized the treatment of cancer patients. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. Healthy Families, Leaps by For more information, go to leaps.bayer.com. Wei Y, Ren X, Galbo PM Jr, et al. NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. The financing will be used to advance NextPoint . IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. designed to prevent, alleviate and treat diseases. KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Janakiram M, Chinai JM, Fineberg S, et al. Bayers leadership in agriculture provides tailored solutions for farmers to plant, grow and protect their harvests using less land, water and energy. Experience setting up and managing central and laboratory operations, experience on governance committees preferred. Importantly, HHLA2 is independent of PD-L1 and is often most strongly expressed in PD-L1-negative cancers. recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. any jurisdiction. Secret of the Bridge, Rice Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. The tender offer referenced herein is not being made, directly or Statements, Questions Infringe any third partys copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy. Use the Website for any purpose that is unlawful or prohibited by these Terms. at the Forefront, Consumer Health & Stories, Working While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. on NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch Portal, Countermotions Salvador, Hong & Medical Devices, Crop Natural Scientists, Global Counterfeits, Recognizing This announcement does not contain or constitute an offer of, The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. The online community has not agreed on what actions, if any, should be taken by the websites that receive the do not track signal, and therefore Do-Not-Track is not yet standardized. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Republic, Ireland, Republic e-mail, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or of Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Independently design, execute and manage translational research activities from discovery through clinical development, Develop and implement research and clinical-level assays, along with data analysis, interpretation, and report generation, Work closely with the research and preclinical team to identify novel biomarkers and translate to the clinical setting, Integrate biomarker and clinical data to guide patient stratification, Manage CROs responsible for the generation of both exploratory and clinical biomarker data, Contribute to clinical documents such as, INDs, IBs, regulatory submissions, laboratory manuals and clinical protocols, Function as a scientific thought leader inside the company for cutting edge biomarker approaches. Stockholders' Meeting, Notice About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. Similar to PD-L1, the tumor antigen HHLA2 is a member of the B7 receptor family1, is highly expressed on certain hard-to-treat cancers2, and drives avoidance of detection from the immune system. Slavery Act Statement, Position Our innovative approach integrates foundational. Governance, Sustainability jurisdictions, only certain categories of person may be allowed to view such materials. One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. Bayer Global Investing in a stronger future - for our shareholders, and for the world. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. 4. Mar 18, 2021, 07:00 ET CAMBRIDGE, Mass., March 18, 2021 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing a novel class of targeted radiopharmaceuticals to treat a. Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. in the Pipeline, Trends in Proc Natl Acad Sci U S A. 24. and Follow-up Questions, How to Procurement Management Trainee Program, Bridging About NextPoint Therapeutics. Experience with Ph 1-3 immuno-oncology clinical trials preferred. Rica, Czech To learn more, visit, Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the Republic of, New Trainee Program for Financial Management, Internal Responsible Lobbying, Climate, Environment and Republic, El Innovation, Bayer 2021 Jul 9;6(61):9792. R&D expenses before special items amounted to 5.3 billion euros. MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. Position, Position Drs. Consulting, Our By clicking on the I AGREE button, I certify that I am not located in the United States, NEXTPOINT THERAPEUTICS, INC. Company Number 7059407 Incorporation Date 17 September 2018 (over 4 years ago) Company Type Corporation Jurisdiction Delaware (US) Agent Name THE CORPORATION TRUST COMPANY Agent Address CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, New Castle, DE, 19801 Directors / Officers THE CORPORATION TRUST COMPANY, agent 13353 Berlin 3+ years experience establishing, managing, and maintaining trial master file applications e.g., Veeva Vault, 5+ years experience with clinical databases e.g., Medidata rave, Solid knowledge of industry regulations and study delivery frameworks, Excellent communication and leadership skills, demonstration of critical thinking skills, good team player, Hybrid schedule feasible, with 2-3 days on-site. Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. HR Trainee Program, International for Prescription Medicine in Europe, Counterfeits in Announcements, Sustainability & Learn more about Bayer and the opportunities available. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients, NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. on An investment decision regarding the securities referred to herein should only We will also retain your Personal Data as necessary to comply with our legal obligations, resolve disputes, and enforce our agreements. Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. The final prospectus, when published, will be available on the website of 50 The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Looking for a job in an innovative company? If you are not permitted to view materials on this webpage or are in any doubt as to whether you are & Audit, International He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. sufficient information on the terms of the offer and any securities to be offered so as to enable an